+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030- Product Image
Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030- Product Image
New

Diabetic Retinopathy Market Size, Share & Trends Analysis Report by Type (Proliferative Diabetic Retinopathy), Management (Anti-VEGF, Intraocular Steroid Injection, Laser Surgery, Vitrectomy), Region and Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 4479737
Description Jump to:
The Diabetic Retinopathy Market was valued at USD 9.48 Billion in 2024, and is projected to reach USD 13.77 Billion by 2030, rising at a CAGR of 6.40%. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

Diabetic Retinopathy Market Report Highlights

  • Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.
  • Laser surgery is expected to grow at the fastest CAGR over the forecast period.
  • The anti-VEGF management segment held the largest market share of 92.3% in 2024.
  • The rise in healthcare investments and advancements in technology contribute to market growth.
  • North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.
  • In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Management
1.2.3. Regional Scope
1.2.4. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type Outlook
2.2.2. Management Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights
Chapter 3. Diabetic Retinopathy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Diabetic Retinopathy Market Analysis tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political Landscape
3.3.2.2. Technological Landscape
3.3.2.3. Economic Landscape
Chapter 4. Diabetic Retinopathy Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. Diabetic Retinopathy Market: Type Movement Analysis
4.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Proliferative Diabetic Retinopathy
4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
4.5. Non-Proliferative Diabetic Retinopathy
4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 5. Diabetic Retinopathy Market: Management Estimates & Trend Analysis
5.1. Management Segment Dashboard
5.2. Diabetic Retinopathy Market: Management Movement Analysis
5.3. Global Diabetic Retinopathy Market Size & Trend Analysis, by Management, 2018 to 2030 (USD Million)
5.4. Anti-VEGF
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5. Intraocular Steroid Injection
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6. Laser Surgery
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7. Vitrectomy
5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 6. Diabetic Retinopathy Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Continuous Bioprocessing Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key Country Dynamics
6.4.1.2. Regulatory Framework/ Reimbursement Structure
6.4.1.3. Competitive Scenario
6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework/ Reimbursement Structure
6.4.2.3. Competitive Scenario
6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.4.3. Mexico
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework/ Reimbursement Structure
6.4.3.3. Competitive Scenario
6.4.3.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key Country Dynamics
6.5.1.2. Regulatory Framework/ Reimbursement Structure
6.5.1.3. Competitive Scenario
6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework/ Reimbursement Structure
6.5.2.3. Competitive Scenario
6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.3. France
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework/ Reimbursement Structure
6.5.3.3. Competitive Scenario
6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.4. Italy
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework/ Reimbursement Structure
6.5.4.3. Competitive Scenario
6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework/ Reimbursement Structure
6.5.5.3. Competitive Scenario
6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.6. Denmark
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework/ Reimbursement Structure
6.5.6.3. Competitive Scenario
6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework/ Reimbursement Structure
6.5.7.3. Competitive Scenario
6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.5.8. Norway
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework/ Reimbursement Structure
6.5.8.3. Competitive Scenario
6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key Country Dynamics
6.6.1.2. Regulatory Framework/ Reimbursement Structure
6.6.1.3. Competitive Scenario
6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework/ Reimbursement Structure
6.6.2.3. Competitive Scenario
6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework/ Reimbursement Structure
6.6.3.3. Competitive Scenario
6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.4. South Korea
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework/ Reimbursement Structure
6.6.4.3. Competitive Scenario
6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework/ Reimbursement Structure
6.6.5.3. Competitive Scenario
6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework/ Reimbursement Structure
6.6.6.3. Competitive Scenario
6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key Country Dynamics
6.7.1.2. Regulatory Framework/ Reimbursement Structure
6.7.1.3. Competitive Scenario
6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.7.2. Argentina
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework/ Reimbursement Structure
6.7.2.3. Competitive Scenario
6.7.2.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key Country Dynamics
6.8.1.2. Regulatory Framework/ Reimbursement Structure
6.8.1.3. Competitive Scenario
6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework/ Reimbursement Structure
6.8.2.3. Competitive Scenario
6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework/ Reimbursement Structure
6.8.3.3. Competitive Scenario
6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework/ Reimbursement Structure
6.8.4.3. Competitive Scenario
6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, by Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key Company Heat Map Analysis, 2024
7.4. Company Profiles
7.4.1. Bayer AG
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. AbbVie Inc.
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Novartis AG
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Oxurion NV.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Sirnaomics, Inc.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Alimera Sciences
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Ampio Pharmaceuticals Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. BCN Peptides
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Kowa Company, Ltd.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Genentech, Inc.
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America diabetic retinopathy market, by country, 2018-2030 (USD Million)
Table 3 North America diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 4 North America diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 5 U.S. diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 6 U.S. diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 7 Canada diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 8 Canada diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 9 Mexico diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 10 Mexico diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 11 Europe diabetic retinopathy market, by country, 2018-2030 (USD Million)
Table 12 Europe diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 13 Europe diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 14 UK diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 15 UK diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 16 Germany diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 17 Germany diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 18 France diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 19 France diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 20 Italy diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 21 Italy diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 22 Spain diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 23 Spain diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 24 Denmark diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 25 Denmark diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 26 Sweden diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 27 Sweden diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 28 Norway diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 29 Norway diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 30 Asia Pacific diabetic retinopathy market, by country, 2018-2030 (USD Million)
Table 31 Asia Pacific diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 32 Asia Pacific diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 33 Japan diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 34 Japan diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 35 China diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 36 China diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 37 India diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 38 India diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 39 South Korea diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 40 South Korea diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 41 Thailand diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 42 Thailand diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 43 Australia diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 44 Australia diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 45 Latin America diabetic retinopathy market, by country, 2018-2030 (USD Million)
Table 46 Latin America diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 47 Latin America surgical ablation market, by management, 2018-2030 (USD Million)
Table 48 Brazil diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 49 Brazil diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 50 Argentina diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 51 Argentina diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 52 MEA diabetic retinopathy market, by country, 2018-2030 (USD Million)
Table 53 MEA diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 54 MEA diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 55 South Africa diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 56 South Africa diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 57 Saudi Arabia diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 58 Saudi Arabia diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 59 UAE diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 60 UAE diabetic retinopathy market, by management, 2018-2030 (USD Million)
Table 61 Kuwait diabetic retinopathy market, by type, 2018-2030 (USD Million)
Table 62 Kuwait diabetic retinopathy market, by management, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Diabetic retinopathy market: market outlook
Figure 10 Diabetic retinopathy competitive insights
Figure 11 Parent market outlook
Figure 12 Related/ancillary market outlook
Figure 13 Penetration and growth prospect mapping
Figure 14 Industry value chain analysis
Figure 15 Diabetic retinopathy market driver impact
Figure 16 Diabetic retinopathy market restraint impact
Figure 17 Diabetic retinopathy market strategic initiatives analysis
Figure 18 Diabetic retinopathy market: Type movement analysis
Figure 19 Diabetic retinopathy market: Type outlook and key takeaways
Figure 20 Proliferative diabetic retinopathy market estimates and forecast, 2018-2030
Figure 21 Non-proliferative diabetic retinopathy estimates and forecast, 2018-2030
Figure 22 Diabetic retinopathy market: Management movement analysis
Figure 23 Diabetic retinopathy market: Management outlook and key takeaways
Figure 24 Anti-VEGF market estimates and forecasts, 2018-2030
Figure 25 Intraocular steroid injection market estimates and forecasts,2018-2030
Figure 26 Laser surgery market estimates and forecasts, 2018-2030
Figure 27 Vitrectomy market estimates and forecasts, 2018-2030
Figure 28 Global diabetic retinopathy market: regional movement analysis
Figure 29 Global diabetic retinopathy market: regional outlook and key takeaways
Figure 30 North America market estimates and forecasts, 2018-2030
Figure 31 U.S. market estimates and forecasts, 2018-2030
Figure 32 Canada market estimates and forecasts, 2018-2030
Figure 33 Mexico market estimates and forecasts, 2018-2030
Figure 34 Europe market estimates and forecasts, 2018-2030
Figure 35 UK market estimates and forecasts, 2018-2030
Figure 36 Germany market estimates and forecasts, 2018-2030
Figure 37 France market estimates and forecasts, 2018-2030
Figure 38 Italy market estimates and forecasts, 2018-2030
Figure 39 Spain market estimates and forecasts, 2018-2030
Figure 40 Denmark market estimates and forecasts, 2018-2030
Figure 41 Sweden market estimates and forecasts, 2018-2030
Figure 42 Norway market estimates and forecasts, 2018-2030
Figure 43 Asia Pacific market estimates and forecasts, 2018-2030
Figure 44 Japan market estimates and forecasts, 2018-2030
Figure 45 China market estimates and forecasts, 2018-2030
Figure 46 India market estimates and forecasts, 2018-2030
Figure 47 South Korea market estimates and forecasts, 2018-2030
Figure 48 Thailand market estimates and forecasts, 2018-2030
Figure 49 Australia market estimates and forecasts, 2018-2030
Figure 50 Latin America market estimates and forecasts, 2018-2030
Figure 51 Brazil market estimates and forecasts, 2018-2030
Figure 52 Argentina market estimates and forecasts, 2018-2030
Figure 53 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 54 South Africa market estimates and forecasts, 2018-2030
Figure 55 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 56 UAE market estimates and forecasts, 2018-2030
Figure 57 Kuwait market estimates and forecasts, 2018-2030

Companies Mentioned

The companies profiled in this Diabetic Retinopathy market report include:
  • Bayer AG
  • AbbVie Inc.
  • Novartis AG
  • Oxurion NV.
  • Sirnaomics
  • Alimera Sciences
  • Ampio Pharmaceuticals Inc.
  • BCNPeptides
  • Kowa Company, Ltd.
  • Genentech, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.77 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Retinal Laser Photocoagulation Market Size, Share & Trends Analysis Report By Laser Type (Diode Laser, Green Laser), By Indication (Proliferative Diabetic Retinopathy), By Modality, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Retinal Laser Photocoagulation Market Size, Share & Trends Analysis Report By Laser Type (Diode Laser, Green Laser), By Indication (Proliferative Diabetic Retinopathy), By Modality, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 130 Pages
  • Global
From
Diabetic Retinopathy Market - Global Forecast to 2030 - Product Image

Diabetic Retinopathy Market - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Retinal Surgery Devices Market Size, Share & Trends Analysis Report By Product, By Application (Diabetic Retinopathy, Retinal Detachment, Epiretinal Membrane, Macular Hole), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Retinal Surgery Devices Market Size, Share & Trends Analysis Report By Product, By Application (Diabetic Retinopathy, Retinal Detachment, Epiretinal Membrane, Macular Hole), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 160 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Diabetic Retinopathy Market Report 2025 - Product Image

Diabetic Retinopathy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.